Observations on three endpoint properties and their relationship to regulatory outcomes of European oncology marketing applications

Lawrence Liberti*, Pieter Stolk, James Neil McAuslane, Jan Schellens, Alasdair M. Breckenridge, Hubert Leufkens

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background. Guidance and exploratory evidence indicate that the type of endpointsand the magnitude of their outcome can define a therapy’s clinical activity; however, little empirical evidence relates specific endpoint properties with regulatory outcomes. Materials and Methods.We explored the relationship of 3 endpoint properties to regulatory outcomes by assessing 50 oncology marketing authorization applications (MAAs; reviewed from 2009 to 2013). Results. Overall, 16 (32%) had a negative outcome. The most commonly used hard endpoints were overall survival (OS) and the duration of response or stable disease. OS was a component of 91% approved and 63% failed MAAs. The most commonly used surrogate endpoints were progression-free survival (PFS), response rate, and health-related quality of life assessments.There was no difference (p =.3801) between the approved and failed MAA cohorts in the proportion of hard endpoints used. A mean of slightly more than four surrogate endpoints were used per approved MAA compared with slightly more than two for failed MAAs. Longer OS and PFS duration outcomes were generally associated with approvals, often when not statistically significant. The approved cohort was associated with a preponderance of statistically significant (p

Original languageEnglish
Pages (from-to)683-691
Number of pages9
JournalOncologist
Volume20
Issue number6
DOIs
Publication statusPublished - 2015

Keywords

  • Accelerated approvals
  • Endpoints
  • Marketing authorization application
  • Oncology
  • Overall survival
  • Progression-free survival

Fingerprint

Dive into the research topics of 'Observations on three endpoint properties and their relationship to regulatory outcomes of European oncology marketing applications'. Together they form a unique fingerprint.

Cite this